-
Product Insights
NewThymoma (Thymic Epithelial Tumor) – Drugs In Development, 2024
Empower your strategies with our Thymoma (Thymic Epithelial Tumor) – Drugs In Development, 2024 report and make more profitable business decisions. Thymoma, also known as thymic epithelial tumor, is a rare type of cancer that originates in the thymus gland, a small organ located behind the breastbone and in front of the heart. The thymus gland plays a role in the development of certain immune cells and is most active during childhood but gradually becomes less active with age. Thymomas are...
-
Product Insights
NewRecurrent Head And Neck Cancer Squamous Cell Carcinoma – Drugs In Development, 2024
Empower your strategies with our Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Recurrent head and neck squamous cell carcinoma (HNSCC) refers to the return of cancer in the head and neck region after initial treatment. HNSCC includes tumors of the oral cavity, pharynx, larynx, and other structures. Recurrence can occur locally, regionally, or distantly. Management of recurrent HNSCC depends on the specific circumstances, including the location and extent...
-
Product Insights
NewThyroid Cancer – Drugs In Development, 2024
Empower your strategies with our Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include a lump that can be felt through the skin on the neck, difficulty swallowing, pain in neck and throat, and swollen lymph nodes in the neck. Predisposing factors include female sex, high levels of radiation exposure, and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy. The Thyroid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Metastatic Transitional (Urothelial) Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Metastatic Transitional (Urothelial) Tract Cancer Drug Details: IK-175 (KYN-175) was under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Recurrent Head And Neck Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Recurrent Head And Neck Squamous Cell Carcinoma Drug Details: IK-175 (KYN-175) was under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Non-Small Cell Lung Cancer Drug Details: IK-175 (KYN-175) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Ovarian Cancer Drug Details: IK-175 (KYN-175) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Pancreatic Cancer Drug Details: IK-175 (KYN-175) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-175 in Colon Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IK-175 in Colon Cancer Drug Details: IK-175 (KYN-175) is under development for the treatment of...